Seagen and LAVA Therapeutics, participated by Ysios, Announce Exclusive Worldwide License Agreement to Advance LAVA-1223

Entorno y otros, Venture Capital

27/09/2022 Nota de prensa SEAGEN AND LAVA THERAPEUTICS ANNOUNCE EXCLUSIVE WORLDWIDE LICENSE AGREEMENT TO ADVANCE LAVA-1223, A PRECLINICAL GAMMA DELTA BISPECIFIC T CELL ENGAGER FOR EGFR-EXPRESSING SOLID TUMORS Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid…

SparingVision Raises €75 Million Series B lead by Jeito and UPMC. Participated 4BIO, Bpifrance, RD fund and Ysios

Inversión, Venture Capital

15/09/2022 Press release SPARINGVISION RAISES €75 MILLION SERIES B TO CONTINUE BUILDING WORLD LEADING PORFOLIO OF GENOMICS FOR OCULAR DISEASES. SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that it has raised €75 million in a Series B financing. The round was co-led by Jeito Capital (“Jeito”) and…